Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site by Huang, Lin-Ya et al.
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid
Binding Site
Lin-Ya Huang,a Ami Patel,a Robert Ng,a* Edward Blake Miller,a* Sujata Halder,a* Robert McKenna,a Aravind Asokan,b,c,d
Mavis Agbandje-McKennaa
Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USAa; Gene Therapy Center,b Department of Genetics,c
and Department of Biochemistry and Biophysics,d University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
ABSTRACT
The adeno-associated viruses (AAVs), which are being developed as gene delivery vectors, display differential cell surface glycan
binding and subsequent tissue tropisms. For AAV serotype 1 (AAV1), the first viral vector approved as a gene therapy treatment,
and its closely related AAV6, sialic acid (SIA) serves as their primary cellular surface receptor. Toward characterizing the SIA
binding site(s), the structure of the AAV1-SIA complex was determined by X-ray crystallography to 3.0 Å. Density consistent
with SIA was observed in a pocket located at the base of capsid protrusions surrounding icosahedral 3-fold axes. Site-directed
mutagenesis substitution of the amino acids forming this pocket with structurally equivalent residues from AAV2, a heparan
sulfate binding serotype, followed by cell binding and transduction assays, further mapped the critical residues conferring
SIA binding to AAV1 and AAV6. For both viruses five of the six binding pocket residues mutated (N447S, V473D, N500E,
T502S, and W503A) abolished SIA binding, whereas S472R increased binding. All six mutations abolished or decreased
transduction by at least 50% in AAV1. Surprisingly, the T502S substitution did not affect transduction efficiency of wild-
type AAV6. Furthermore, three of the AAV1 SIA binding site mutants—S472R, V473D, and N500E—escaped recognition
by the anti-AAV1 capsid antibody ADK1a. These observations demonstrate that common key capsid surface residues dic-
tate both virus binding and entry processes, as well as antigenic reactivity. This study identifies an important functional
capsid surface “hot spot” dictating receptor attachment, transduction efficiency, and antigenicity which could prove useful
for vector engineering.
IMPORTANCE
The adeno-associated virus (AAV) vector gene delivery system has shown promise in several clinical trials and an AAV1-based
vector has been approved as the first gene therapy treatment. However, limitations still exist with respect to transduction effi-
ciency and the detrimental effects of preexisting host antibodies. This study aimed to identify key capsid regions which can be
engineered to overcome these limitations. A sialic glycan receptor recognition pocket was identified in AAV1 and its closely re-
lated AAV6, using X-ray crystallography. The site was confirmed bymutagenesis followed by cell binding and transduction as-
says. Significantly, residues controlling gene expression efficiency, as well as antibody escape variants, were also identified. This
study thus provides, at the amino acid level, information for rational structural engineering of AAV vectors with improved ther-
apeutic efficacy.
Adeno-associated viruses (AAVs) are small, nonenveloped,single-stranded DNA packaging viruses that belong to the
Dependoparvovirus genus of theParvoviridae. There are more than
150 naturally occurring variants, and 13 nonhuman and human
serotypes have been described (1–6). Due to their nonpathogenic-
ity, ability to package recombinant DNA, long-term transgene
expression, and ability to transduce dividing and nondividing
cells, the AAVs are being developed as gene delivery vectors (7, 8).
The most studied serotype, AAV2, exhibits broad tissue tropism,
while several other serotypes exhibit better specific tissue trans-
duction (9–18). Examples include AAV1 transduction of smooth
muscle, the central nervous system, and retina at 1,000-, 35-, and
2-fold better, respectively (13–15), while AAV6 has superior
smooth muscle, heart, and lung transduction by 500-, 10-, and
10-fold, respectively, compared to AAV2 (16–18). Diversity in the
tissue tropism of different AAV serotypes extends their utility for
the delivery of a large number of different genes for the treatment
of a variety of genetic disorders.
However, despite the promise of the AAV as efficient gene de-
livery systems, several challenges need to be overcome for full
clinical realization. This includes targeting specificity which is af-
fected by (i) tissue tropism, with broad recognition resulting in
less effective tissue specific application, and (ii) administration
route, with direct or systemic injection affecting transgene expres-
sion profiles (19). Second, preexisting anti-AAV antibodies
against different serotypes are found in 40 to 70% of the human
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population because of natural exposure to the viruses (20, 21).
This leads to decreased therapeutic efficacy and reduces the pop-
ulation eligible for AAV vector treatment, with only immunolog-
ically privileged organs, such as the eye, being more amenable to
viral vector delivery (22, 23). Capsid modifications such as muta-
tions at critical antigenic sites (24) and rational capsid residue
substitutions and insertion (25) have been used to generate anti-
body escape variants, as well as vectors with enhanced transduc-
tion. Since single residue mutations can result in dramatic effects
on virus phenotypes (25, 26), it is important to understand how
host cell molecules and antibodies interact with virus capsid.
The T1 icosahedral capsid of AAVs are assembled from 60
copies of three overlapping viral proteins (VPs), VP1, VP2, and
VP3 in a ratio of 1:1:10 (27, 28). The entire sequence of VP3 is
contained within VP2, which is in turn contained within VP1. The
VP1 thus contains a unique region, VP1u, and shares a common
VP1/2 region with VP2. Superposition of the structurally ordered
VP3 of available AAV serotype structures shows a core eight-
stranded antiparallel -barrel (BIDG-CHEF) motif and a con-
served -helix (A), with variable loops inserted between these
secondary structure elements (29). A total of nine variable regions
(VRs) were defined within the loop insertions based on the com-
parison of two serotypes, AAV2 and AAV4, which differ in se-
quence and structure (30). The VR loops constitute the exterior
capsid surface and dictate serotype diversity, such as capsid topol-
ogy, tissue tropism, antibody recognition, and transduction prop-
erties (30–33). The capsid surface is characterized by a depression
at the icosahedral 2-fold axis, protrusions surrounding a depres-
sion at the 3-fold axis, and a cylindrical channel at the 5-fold axis
surrounded by a canyon-like depression (29).
Glycan receptors on cell surfaces facilitate the first step of many
virus-host interactions and dictate virus host tissue tropism. Dif-
ferent AAV serotypes have evolved to use different glycan recep-
tors for cell entry. These can be classified into three broad groups
(34): (i) sialic acid (SIA) binders (AAV1, AAV4, AAV5, and
AAV6) (35, 36), (ii) heparan sulfate proteoglycan (HSPG) binders
(AAV2, AAV3, AAV6, and AAV13) (4, 26, 37, 38), and (iii) galac-
tose binders (AAV9) (39, 40). AAV1 and AAV6, in group i, are
closely related, differ by 6/736 amino acids (99.2% sequence iden-
tity), and recognize 2-3 and 2-6 N-linked SIA (35). In addition
to SIA, AAV6 also binds HSPG dictated by the single K531E amino
acid difference to AAV1 (26).
In this study, X-ray crystallography was used to identify the SIA
binding site for AAV1, located on the base of the protrusions
surrounding the icosahedral 3-fold axis of the capsid. Mutagenesis
combined with cell binding and transduction assays confirmed
N447, S472, V473, N500, T502, and W503 as being important for
AAV1 and AAV6 SIA interaction. In addition, an overlap between
the SIA binding site and the AAV1 ADK1a antigenic epitope (41)
was confirmed by native dot blot analysis, enzyme-linked immu-
nosorbent assay (ELISA), and antibody neutralization assay, sug-
gesting steric hindrance of receptor attachment as the neutraliza-
tion mechanism of this antibody. This study thus provides
information for AAV1 and AAV6 determinants of cellular recog-
nition, as well as for their engineering to escape from antibody
recognition.
MATERIALS AND METHODS
Cell Culture. Human embryonic kidney 293 (HEK293) cells were cul-
tured in Dulbecco modified Eagle medium (Gibco, catalog no. 12100-
046) supplemented with 10% fetal bovine serum and 1% antibiotic-anti-
mycotic (Gibco, catalog no. 15240-052). The Chinese hamster ovary
(CHO) cell lines Pro-5, Lec-2, Lec-8, and Lec-1 were obtained from the
American Type Culture Collection (www.atcc.org). All of the CHO cells
were cultured in -minimum essential (-MEM) medium (Gibco, cata-
log no. 32571-036) supplemented with 10% fetal bovine serum and 1%
antibiotic-antimycotic. Cells were grown at 37°C in a 5% CO2 atmo-
sphere.
Structure determination of the AAV1-SIA complex. Expression and
crystallization of the AAV1 virus-like particles (VLPs) have been previ-
ously described (42). Briefly, crystals of the AAV1 VLPs were grown at
room temperature using the hanging-drop vapor diffusion method in
buffer containing 0.1 M HEPES-NaOH (pH 7.3), 50 mM MgCl2, 0.03%
NaN3, 1.0 M NaCl, 7% polyethylene glycol 6000, and 25% glycerol. Crys-
tals were soaked into cryoprotectant solution (25% glycerol) containing a
10-fold molar excess (relative to VP binding sites) of a trisaccharide,
3=SLDN (Neu5Ac2-3GalNAc1-4GlcNAc) for 48 h and flash cooled in
liquid nitrogen vapor prior to X-ray diffraction data collection. A total of
229 X-ray diffraction images were collected from one crystal at the A1
beamline at the Cornell High Energy Synchrotron Source (CHESS; Cor-
nell University, Ithaca, NY). The data collection parameters were as fol-
lows: crystal-to-detector distance of 300 nm and an oscillation angle of
0.3° per image, with an exposure time of 70 s per image at a wavelength of
  0.979 Å.
The images were indexed, integrated, scaled, and merged using the
HKL2000 suite (43). The crystals diffracted X-rays to 3.0-Å resolution.
The crystals were shown to be monoclinic C2 with unit cell dimensions of
a 455.6, b 261.8, c 451.0 Å, 90°, and 111.0°. TheRmerge
and completeness values were 16.3 and 61.6%, respectively. The data pro-
cessing statistics are provided in Table 1.
Based on the unit-cell volume and packing considerations, it was de-
termined that there were four VLPs in the unit cell. The particle orienta-
tions were determined by self-rotation function searches using the GLRF
program (44). Two particle orientations were observed, each with a non-
crystallographic symmetry (NCS) 2-fold axis coincident with the crystal-
lographic 2-fold axis, resulting in two independent half-capsids per asym-
metric unit. The particles were positioned at (0.0,0.0,0.0) and (0.5,0.5,0.0)
for the first orientation (Wyckoff notation a) and at (0.0,0.5,0.5) and
(0.5,0.0,0.5) for the second orientation (Wyckoff notation b). Initial
phases were calculated using the automr subroutine (molecular replace-
ment) in the PHENIX program (45) with a 30-mer Cmodel of the AAV1
VP3 monomer structure (PDB accession no. 3NG9).
After the automr procedure with the Cmodel, which confirmed the
presence of two half capsids (2  30-mers) in the crystallographic asym-
metric unit, a cycle of refinement was carried to improve the initial phases
using the phenix.refine subroutine in the PHENIX program. The refer-
ence VP3 C monomer was extracted from the starting 30-mer model, a
polyalanine model of the AAV1 VP3 was superposed onto it, and the
structure was converted to the wild-type (WT) AAV1 sequence by inter-
active substitution based on the resulting electron density map using the
COOT program (46–48). The two half-capsids were then generated from
the new VP3 model using NCS. Phases were improved by alternative
interactive model building into averaged density maps using the COOT
program (46–48), followed by coordinate refinement using the PHENIX
program (49–51). After three rounds of this process, unassigned electron
density on the exterior surface of the capsid that was not part of the VP3
and at a sigma (	) threshold of 1.8 in an averaged “Fo
Fc” (where Fo and
Fc represent the observed and calculated structure factor amplitudes, re-
spectively) difference map, was interpretable as a SIA molecule associated
with 30/60 VP molecules being used in the refinement process. The
coordinate of a SIA was imported from the ligand library in the COOT
program and manually docked into the averaged Fo
Fc difference map
using the COOT program (46). The fitting of the docked SIA was refined
against an averaged Fo
Fc difference map using “Real Space Refine Zone”
in COOT and the coordinates of the AAV1-SIA complex were refined in
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PHENIX. The potential amino acids that interact with the SIA molecule
were determined to be those with distances of 4 Å. The quality of the
refined structure was analyzed by the MolProbity application (76). The
data collection, processing, and refinement results are presented in
Table 1. The figures were generated using the PyMOL program (52).
The “Roadmap” image, depicting capsid surface accessible amino acid
residues, was generated using the RIVEM program (53).
Generation of recombinant AAV (rAAV) mutant plasmid con-
structs. SIA binding site mutants were designed based on the observed
structural contacts between the AAV1 capsid and SIA (see above) and
generated using the QuikChange Lightning site-directed mutagenesis kit
(Agilent Technologies, catalog no. 210518-5) as described in the manu-
facturer’s protocol. For each residue mutated, two complementary prim-
ers were used to introduce changes into the pXR1 (AAV1) or pXR6
(AAV6) plasmids with a single amino acid mutated to its structurally
corresponding residue on AAV2, a HSPG binding serotype. The primers
used to generate all these mutants are listed in Table 2. All of the mutants
were sequenced before further analysis, and the plasmids were purified by
the CsCl DNA extraction method.
Expression and purification of WT and mutant rAAV vectors. The
rAAV vectors were generated in HEK293 cells by triple plasmid transfec-
tion (54). The plasmids used were the WT pXR1 or pXR6 or mutant
capsid plasmids, pTR-Flag-Luciferase (Luc) reporter plasmid, and pXX6
helper plasmid (54). Ten 15-cm2 plates, seeded with HEK293 cells, were
grown to 90% confluency and transfected by polyethyleneimine with the
plasmids in a molar ratio of 1:1:3 (pXR:pTR-Flag-Luciferase:pXX6) for a
total of 90 g of plasmid DNA per plate. After 72 h, the cells were har-
vested and resuspended in TNET (500 mM Tris-HCl [pH 8.0], 300 mM
NaCl, 5 mM EDTA, 0.06% Triton X-100), subjected to three rounds of
freeze-thawing, and treated with 100 U/ml Benzonase (Millipore, catalog
no. 71205-3) at 37°C for 30 min after the last thaw. The cell debris was
removed by centrifugation at 3,500  g for 10 min, and the supernatant
was purified by iodixanol gradient ultracentrifugation and ion exchange
using a HiTrap Q HP column (GE Healthcare, catalog no. 17-5158-01)
(55). Fractions containing purified rAAV-Luc vectors were combined,
concentrated, and dialyzed into phosphate-buffered saline (PBS) prior
to use.
Negative-stain EM. Portions (5 l) of purified samples were loaded
onto carbon-coated copper electron microscopy (EM) grids (Ted Pella)
and incubated at room temperature for 5 min. The grids were blotted dry
using filter paper (Whatman) and stained with Nano-W (Nanoprobes,
catalog no. 2018) for 10 s. The grids were blotted with filter paper again to
remove the staining solution and left at room temperature until com-
pletely dry. Micrographs were collected by imaging the grids on a Tecnai
G2 Spirit transmission EM (FEI) microscope operated at an accelerating
voltage of 120 keV.
Virus genome titer and capsid assembly quantification.The genome
titer of rAAV-Luc vectors was determined based on the packaged lucifer-
ase gene. To remove unpackaged DNA prior to packaged genome quan-
TABLE 1 Data collection, processing, and refinement statistics of
AAV1-SIA
Parameter AAV1-SIA
Data collection and processing
Wavelength (, Å) 0.979 (CHESS)
No. of films 229
Space group C2
Unit cell parameters
a, b, c (Å) 455.6, 261.8, 451.0
 (°) 111.0
Resolution (Å) 50.0–3.0
Total no. of reflections 1,170,740
No. of unique reflections 593,352
Rmerge
a (%) 16.3
Completeness (%) 61.6
I/	 5.3
Refinement
Rfactor
b (%) 26.8
Rfree
c (%) 27.6
No. of atoms 249,660
RMSD
Bond (Å) 0.008
Angle (°) 1.065
Ramachandran statistic (%)
Favored 92.9
Allowed 100
Outliers 0
Avg B factor (Å)
Main chain 21.8
Side chain 23.2
Ligand 32.3
a Rmerge  (|Ihkl 
 Ihkl |/|Ihkl|)  100, where Ihkl is the intensity of an individual
“hkl” reflection, and Ihkl is the mean intensity for all measured values of this
reflection.
b Rfactor  (||Fobs| 
 |Fcalc||/|Fobs|)  100, where Fobs and Fcalc are the amplitudes
for the observed and calculated reflections, respectively.
c Rfree was calculated with 5% of the reflections excluded from the data set during
refinement.
TABLE 2 Primer for generating SIA binding defective mutants and titer quantification
Primer (VP aa)a Sequence (5=–3=)
N447S-F CCAATACCTGTATTACCTGAGCAGAACTCAAAATCAG
N447S-R CTGATTTTGAGTTCTGCTCAGGTAATACAGGTATTGG
S472R-F CTCCAGCTGGCATGCGGGTTCAGCCCAAAAACTG
S472R-R GGGCTGAACACGCATGCCAGCTG
V473D-F GCTGGCATGTCTGACCAGCCCAAAAACTGGC
V473D-R CAGTTTTTGGGCTGATCAGACATGCCAG
N500E-F CAGACAACAACAACAGCGAATTTACCTGGACTGGTGCTTC
N500E-R GCACCAGTCCAGGTAAATTCGCTGTTGTTGTTG
T502S-F CAACAACAGCAATTTTTCGTGGACTGGTGCTTC
T502S-R TTTTGAAGCACCAGTCCACGAAAAATTGCTGTTGTTGTTG
W503A-F CAACAGCAATTTTACCGCTACTGGTGCTTCAAAATATAACC
W503A-R GGTTATATTTTGAAGCACCAGTAGCGGTAAAATTGCTGTTG
Luciferase-F ATTACACCCGAGGGGGATGA
Luciferase-R CTCTCACACACAGTTCGCCT
a aa, amino acid.
AAV1 and AAV6 SIA Glycan Receptor Interactions
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tification, 10 l of each purified rAAV vector was first treated with 1 U of
benzonase in a total 200-l reaction mixture containing 20 mM Tris-HCl
(pH 8.5), 15 mM NaCl, and 2 mM MgCl2 at 37°C for 30 min. The pack-
aged reporter gene was then released by adding 22 l of proteinase K
buffer (100 mM Tris HCl [pH 8.0], 100 mM EDTA, 10% sodium dodecyl
sulfate) to the reaction mixture, followed by 2 l of proteinase K (18.6
mg/ml; Fisher, catalog no. BP1700-05). The reaction was carried out at
37°C for 30 min, and the reporter gene was twice extracted by using phe-
nol-chloroform-isoamyl alcohol, followed by ethanol precipitation. The
genome titer of each rAAV-Luc vector was determined by quantitative-
PCR (q-PCR) using primers (Table 2) targeting the pTR-Flag-Luciferase
gene as previously described (55).
The capsid titer of the rAAV-Luc vectors was determined by an ELISA.
Fourteen nanograms of cell lysate protein were used for each vector prep-
aration. The assay was conducted as described in the AAV1 ELISA kit
according to the manufacturer’s protocol (Progen, catalog no. PRAAV1).
Cell binding assay. Pro-5 cells were trypsinized from 10-cm2 plates
and washed twice with cold serum-free -MEM medium (Gibco, catalog
no. 32571-036). The resuspended cells were added to 1.5-ml centrifuge
tubes at 2.5 105 cells/tube in 50l of cold serum-free-MEM medium.
The cells were cooled to 4°C for 15 min before vector was added. Each
rAAV-Luc vector was resuspended in 50 l of cold serum-free -MEM
and added to the cells at a titer of 2.5  1010 vector genomes (vg)/tube
(multiplicity of infection  105). After incubation at 4°C for 90 min, the
cells were collected and washed three times with cold PBS. The luciferase
gene in bound vectors was extracted and quantified by q-PCR as described
above.
Transduction assay. CHO cell lines (Pro-5, Lec-2, Lec-8, and Lec-1)
were seeded overnight at 5  104 cells/well into a 96-well plate. The cells
were then washed with cold PBS, and 50 l of cold serum-free -MEM
was added. After cooling down to 4°C for 15 min, rAAV-Luc vectors, at
5  109 vg in 50 l of serum-free -MEM, were added to each well,
followed by incubation at 4°C for another 90 min. The cells were washed
three times with cold PBS, warm complete -MEM was added, and they
were incubated in a CO2 culture incubator for 48 h. Luciferase expression
was determined by a luciferase assay (Promega, catalog no. E1500) as
described in the manufacturer’s protocol.
Native dot blot assay. To check for potential overlap of the SIA bind-
ing site with antigenic epitopes, the WT and mutant rAAV-Luc vectors
were tested for reactivity against four different mouse monoclonal anti-
bodies (MAbs)—ADK1a, ADK1b, 5H7, and 4E4 — directed against WT
AAV1 capsids (56, 75) and the B1 MAb that reacts against denatured AAV
VPs (57). One hundred nanograms of the rAAV-Luc vectors in TNET
buffer was used for native dot blot experiments. Each rAAV-Luc sample
was loaded onto a nitrocellulose membrane (Amersham, catalog no.
10600007) using the Spot-Blot system (GE Healthcare). The unboiled
vectors were blotted with hybridoma supernatant for ADK1b and 5H7
and purified antibodies for ADK1a and 4E4 produced as previously de-
scribed (41, 58). Briefly, hybridoma supernatant isolated from cells pro-
ducing the MAb was purified by Hi-Trap protein G HP columns (GE
Healthcare). The intact IgG antibodies were eluted with glycine-HCl (pH
2.7) directly into 1 M Tris-HCl (pH 9.0) to achieve a neutral pH. The
boiled samples were blotted with B1 (ARP, catalog no. 365158). Horse-
radish peroxidase-conjugated anti-mouse IgG (GE Healthcare, catalog
no. NA931V) was used as secondary antibody, and the signal was detected
by chemiluminescent reagent (Millipore, catalog no. WBKLS0500).
Neutralization assay. To determine the ability of the AAV1 S472R
mutant, which showed reduced binding by ADK1a, to escape neutraliza-
tion by the IgG, purified ADK1a MAb was used. Briefly, Pro-5 cells were
seeded at 5 104 cells/well in a 96-well plate and incubated at 37°C for 24
h. The rAAV-Luc vectors were preincubated with ADK1a at five different
IgG/capsid ratios (6:1, 12:1, 30:1, 60:1, and 120:1) at 37°C for 30 min. The
vector and antibody complexes were added to the cells in the appropriate
volumes (based on the titer) required to achieve 5  109 vg/well. The
expression of luciferase was assessed 48 h postinfection according to the
manufacturer’s protocol.
Coordinates.The coordinates and structure factors for the AAV1-SIA
complex structure have been deposited in the PDB database (http://www
.rcsb.org/) under accession number 5EGC.
RESULTS
The base of the 3-fold protrusions serves as the AAV1 SIA bind-
ing pocket. The AAV1-SIA crystal diffracted X-rays to 3.0-Å res-
olution. The data set was 61.6% complete and the overall Rmerge
was 16.3% after data processing and reduction. After refinement,
the R-work, indicating the quality of the data by measuring the
agreement between the experimentally observed data and the
model built into the electron density, is 26.8% (Table 1). These
values are within acceptable range as shown in previously pub-
lished virus structures at comparable resolution, including other
AAV structures (30, 59). As reported for other AAV structures, the
VP was ordered from residue 217 within the VP3 common region,
with the VP1u and VP1/2 common regions being disordered (29).
The ordered VP3 region exhibited the secondary structure topol-
ogy of the AAVs, including the nine VRs previously described
when superposed onto other AAV VP structures (not shown). The
AAV1 capsid structure exhibited the structural characteristics pre-
viously reported for other AAVs, including the depressions at the
icosahedral 2-fold and surrounding the 5-fold axes, protrusions
surrounding the 3-fold axis, and channel at the 5-fold axis (Fig.
1A) (29, 59). Density for the single nucleotide residue ordered
inside a pocket in most AAV structures determined to date (for
example, see reference 59) was also observed in this complex
structure (not shown).
The AAV1 crystal was soaked with the trisaccharide, Neu5Ac2-
3GalNAc1-4GlcNAc (3=SLDN), which was identified as a top hit
glycan interacting with AAV1 using a glycan microarray (35). How-
ever, only ordered electron density interpretable as the terminal SIA
molecule was observed at the base of the protrusions surrounding
icosahedral 3-fold axis (Fig. 1A and B). This indicates that the remain-
ing GalNAc1-4GlcNAc moiety is flexible and/or not ordered. The
terminal SIA was easily identifiable at a 	 threshold of 1.8 and 0.5 in
the averaged Fo
Fc and 2Fo
Fc density maps, respectively. Refine-
ment of the SIA with a 0.5 occupancy resulted in SIA atom tempera-
ture factors (B-factors) within the range of those for the surrounding
VP residue atoms with occupancy of 1.0 (Table 1). The SIA binding
pocket is formed by two 3-fold symmetry related VP3 monomers
contributed by three VRs: VR-I, VR-IV, and VR-V. Nine amino acids
were identified as potential SIA binding contacts, based on a distance
contact criteria of4 Å between the SIA atoms and the capsid. These
residues are as follows: S268, D270, and N271 in VR-I; N447, S472,
and V473 in VR-IV; and N500, T502, and W503 in VR-V (Fig. 1B).
AAV1 and AAV6 utilize the same SIA binding pocket. To
confirm the structurally predicted AAV1 SIA binding residues, a
structural alignment of the AAV1 VP3 with that of the HS binding
AAV2 was performed. The five (out of the nine) residues which
differed—N447, S472, V473, N500, and T502 (Table 3)—were
mutated to their structurally corresponding amino acids in AAV2
in the AAV1 background for characterization. Tryptophan 503,
conserved in AAV1, AAV2, and AAV9, was mutated to an alanine
(Table 3).
The amino acid composition of the SIA binding pocket is iden-
tical between AAV1 and AAV6 (Table 3). The 5/6 residues (out of
736) which differ between the two viruses that are ordered in their
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structures are E531K, F584L, and A598V (AAV1/AAV6), located
around the 3-fold axis on the exterior capsid surface (Fig. 1A), and
E418D and N642H located on the interior capsid surface, also
close to the 3-fold axis (59). Residue L129F located within the
VP1u is disordered in all AAV structures determined to date. The
AAV1/6 differing residues ordered in the crystal structure do not
overlap with those in the AAV1 SIA binding pocket (Fig. 1A); thus,
it was rationalized that the dual glycan binding AAV6 may also
utilize the same pocket as AAV1 to interact with SIA. Thus, the
role of the pocket residues in SIA binding and cell transduction
was tested for AAV6 alongside AAV1.
Negative-stain EM showed that all SIA site mutants formed
intact capsids (Fig. 2A and C). Quantification of the luciferase
reporter gene packaged inside the capsids by q-PCR showed no
DNA packaging defects (Fig. 2B and D), except for mutant
rAAV6-N447S, which showed a 100-fold decrease in packaged
genome copy number compared to WT rAAV6. This defect in
AAV6, but not in AAV1, is difficult to explain because the six
residues which differ between AAV1 and AAV6 are not proximal
to the SIA binding pocket. Thus, how this residue is affecting the
packaging phenotype for AAV6 is unknown. Due to its packaging
defect, the rAAV6-N447S mutant was excluded from analysis of
cell binding and transduction efficiency of the binding pocket mu-
tants compared to the WT virus.
Structurally predicted SIAbinding residues are important in
SIA-dependent cell attachment. Cell binding assays with the pa-
rental CHO cell Pro-5, which displays SIA as a terminal glycan,
showed a decrease for 5/6 AAV1/6 mutants: N447S, V473D,
N500E, T502S, and W503A (Fig. 3). This confirmed the impor-
tance of these residues in SIA binding for both serotypes. How-
ever, unexpectedly, the mutant S472R showed an increased/com-
parable Pro-5 cell binding in AAV1 and AAV6 (Fig. 3). To test the
possibility that the polar to basic residue change in S472R con-
ferred a new binding phenotype for negatively charged molecules
on the cell surface, such as the HS utilized by AAV2, a heparin
column was used to test the affinity of this variant compared to
AAV2. The result showed that S472R does not bind to the HS
(data not shown). These observations indicate that this AAV1 and
AAV6 residue is involved in initial cell engagement during infec-
tion and that the serine-to-arginine change alters the SIA interac-
tion, possibly increasing affinity.
Structurally predicted SIA binding residues are involved in
SIA-mediated cell transduction. The infectivity of the AAV1 and
AAV6 SIA binding mutants were tested in CHO cells with differ-
ent levels of surface glycosylation to further assess the role of dif-
TABLE 3 SIA binding pocket residue alignment (in VP1 numbering)a
AAV1 AAV2 AAV6 AAV9
S268 S268 S268 S269
D270 D271 D270 D271
N271 N272 N271 N272
Y445 Y445 Y445 Y446
N447 S446 N447 S448
G470 G470 G470 N470
S472 R471 S472 A472
V473 D472 V473 V473
N500 E499 N500 E500
T502 S501 T502 A502
W503 W502 W503 W503
SIA HS SIA GAL
a Residues in boldface indicate amino acids that play a role in binding the glycan
indicated for each serotype. Underlined residues for AAV2 are the type to which
structurally equivalent AAV1 and AAV6 residues were substituted to eliminate SIA
binding.
FIG1 SIA binding site on the AAV1 capsid. (A) Capsid surface image of AAV1
with the location of observed SIA density (yellow) and three surface-exposed
residues that differ between AAV1 and AAV6: E531K (red), F584L (blue), and
A598V (orange, not visible in the orientation shown). A viral asymmetric unit
is depicted by a triangle (in black) bounded by two 3-fold (filled triangle) axes,
divided by a line drawn through the 2-fold (filled oval) and a 5-fold (filled
pentagon) axis. (B) Stick representation of a section of the AAV1-SIA crystal
structure and predicted SIA interacting residues. The binding pocket is formed
by two monomers with chains designated A and B. Some of the residues are
located at two variable regions: (i) VR-I for S268, D270, and N271; (ii) VR-IV
for N447, S472, and V473; (iii) VR-V for N500, T502, and W503. The electron
density map of SIA is an averaged 2Fo
Fc map shown at a sigma threshold of
2.0 with radius cutoff (carve) of 1.9 Å. This figure was generated using the
PyMOL program (52).
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ferent cell surface glycans (Fig. 4). In addition to the Pro-5 cells,
Lec-2 (deficient in the CMP-sialic acid Golgi transporter and
exposes terminal galactose on surface glycans), Lec-8 (deficient
in the UDP-galactose Golgi transporter and displays terminal
N-acetylglucosamine on surface glycans), and Lec-1 (deficient in
the N-acetylglucosaminyltransferase and displays terminal man-
nose on surface glycans) were tested. The transduction by WT
rAAV1 was significantly decreased (72%) on the terminal SIA
devoid cell line Lec-2 compared to the parental Pro-5 cell line (Fig.
4A). Transduction by rAAV1 mutants, N447S, V473D, N500E,
T502S, and W503A, defective in Pro-5 binding also showed a
63% reduction in transduction in Pro-5 cells compared to WT
rAAV1. Interestingly, although rAAV1-S472R showed a 2-fold in-
crease in Pro-5 cell binding compared to the WT virus, the trans-
duction ability of this mutant was also reduced by68% in these
cells. The transduction efficiency of WT rAAV1 was reduced to
30, 40, and 60% in the Lec-2, Lec-8, and Lec-1, respectively;
while the mutants had negligible transduction levels (Fig. 4A).
The transduction level of WT rAAV6 is also decreased in Lec-2,
Lec-8, and Lec-1 cells (Fig. 4B). Four mutants—S472R, V473D,
N500E, and W503A—showed a50% reduction in transduction
FIG 2 WT AAV and SIA-binding site mutant characterization. (A and C)
Negative stain micrographs and (B and D) genome packaging titers of WT
AAV and SIA binding site mutants. Panels A and B show results for AAV1,
and panels C and D show results for AAV6. The genome packaging titers
were determined by q-PCR. The values are means from three experiments
displayed in a log scale; the error bars represent standard deviations. vg,
vector genome.
FIG 3 Pro-5 cell binding. The binding of AAV1 (A) and AAV6 (B) WT and
SIA binding site mutants to Pro-5 cells. Data are normalized to the WT (1.0) in
the y axis. The values are means from three experiments; the error bars repre-
sent standard deviations.
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of Pro-5 cells. These same four mutants did not transduce the
Lec2, Lec8, and Lec1 cells, an observation consistent with their
lack of binding to Pro-5 cells. Surprisingly, mutant T502S trans-
duced Pro-5 cell at the same level as WT AAV6 despite an 80%
decrease in cell binding compared to the WT virus. This suggests a
gain of function related to postentry events for this mutant that is
not related to SIA binding.
SIA binding site overlaps with AAV1ADK1a epitope. Several
residues in the SIA binding site overlap amino acids reported to
form the antigenic footprint for the ADK1a MAb directed against
the AAV1 capsid (Fig. 5A) (41). Thus, the possibility that this MAb
neutralizes infection due to steric hindrance of the receptor at-
tachment was explored. A native dot blot showed that three of the
SIA binding mutants, S472R, V473D, and N500E, can escape from
ADK1a recognition but not from MAbs ADK1b, 5H7, and 4E4,
which are also directed against the AAV1 capsid but have dif-
ferent epitopes (Fig. 5B). This observation is consistent with
the overlap of the SIA binding site with only the mapped
ADK1a footprint (Fig. 5A). This escape from ADK1 was further
confirmed by an ELISA using ADK1a as primary antibody (Fig.
5C). The rAAV1-S472R that still retained a reduced level of
Pro-5 transduction (30% compared to WT) was thus tested
for its ability to escape neutralization during infection in these
cells. WT rAAV1 preincubated with ADK1a IgG prior to infec-
tion showed a dose-dependent decrease in transduction level in
Pro5 cells with increasing ADK1a-to-capsid ratios (Fig. 6A). In
contrast, the rAAV1-S472R transduced Pro5 cells in the pres-
FIG 4 Transduction assays in CHO cells. Transduction by AAV1 (A) and
AAV6 (B) WT and SIA binding mutants in Pro-5, Lec-2, Lec-8, and Lec-1, as
indicated in panel A. Data are normalized to WT transduction in Pro-5 cells set
to 1 in the y axis. The values are means from three experiments; the error bars
represent standard deviations.
FIG 5 Antigenic reactivity of SIA binding mutants. (A) Stereographic Roadmap
projection of the epitopes mapped for AAV1 specific antibodies: ADK1a (purple),
ADK1b (gray), 5H7 (green), and 4E4 (blue), along with SIA binding site (yellow).
Residues that overlap between the ADK1a epitope and the SIA binding site are
colored in red. (B) Dot blot analysis of SIA binding mutants against AAV1 anti-
bodies: ADK1a, ADK1b, 5H7, and 4E4. (C) ELISA results for AAV1 SIA mutants
using ADK1a as primary antibody. Data are normalized to WT set to 1 in theyaxis.
The values are means from three experiments; the error bars represent standard
deviations. Panel A was generated using the RIVEM program (53).
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ence of 120 IgG molecules per capsid, which is equivalent to
two MAb molecules per VP (Fig. 6B). These data indicate that
ADK1a neutralizes AAV1 infection at the viral entry stage by
blocking attachment.
DISCUSSION
Capsid modification via rational design is a tested strategy for
overcoming challenges still remaining for the AAV delivery sys-
tem. This approach can be used to generate new chimeric viruses
by swapping or mutating specific capsid residues or regions be-
tween different serotypes based on the sequence and structural
information to achieve desired functional phenotypes. An exam-
ple is the liver detargeting and muscle tropic chimera, AAV2i8,
generated by substituting a hexapeptide from AAV8 into AAV2’s
HS binding region based on structural information (60). Another
example is the enhanced muscle-tropic chimera, AAV2.5, gener-
ated by introducing five residues from muscle tropic serotype
AAV1 into the AAV2 background (61). Both of these chimeras
showed altered transduction and antigenic profiles, including es-
cape from antibody recognition compared to the WT parental
vectors. Therefore, knowledge of capsid structures and mapped
capsid regions that engage in cellular interaction is important for
capsid manipulation for improved vector efficacy.
The structure of the AAV1-SIA complex was determined in an
effort to identify the capsid region utilized for cell entry interac-
tions. This region was mapped to a capsid surface pocket at the
base of the 3-fold protrusion on AAV1 capsid and confirmed to
play an essential role in cell binding and transduction for AAV1
and the closely related AAV6. Significantly, a structurally analo-
gous pocket serves as the galactose (GAL) binding pocket in AAV9
(40). Residues dictating AAV9 GAL binding are D271, N272,
Y446, N470, A472, V473, and W503 identified by mutagenesis and
ligand docking (40). Structural alignment of the glycan binding
pockets showed that 5/11 residues are different between AAV1/6
and AAV9 (Table 3). Among these residues, the long side chain of
AAV9 N470, shown to be critical for its interaction with GAL,
clashes with the modeled SIA molecule in the AAV1-SIA complex
and would likely hinder an interaction (Fig. 7). This residue is a
glycine in AAV1. Therefore, residue 470 may be the glycan usage
determinant for AAV1 and AAV9.
Site-directed mutagenesis of the amino acids forming the SIA
binding pocket in AAV1 and AAV6 to their structurally equivalent
residue types in AAV2 confirmed the role of 5/6 residues mutated
FIG 6 Neutralization of WT AAV1 and the AAV1-S472R infection of Pro-5
cells by ADK1a. Cell transduction by WT AAV1 (A) and AAV1-S472R (B),
respectively, preincubated with ADK1a antibody was assessed. The ratios
shown are ADK1a IgG molecules per capsid. Data are normalized to virus only
set to 1 in the y axis. The values are means from three experiments; the error
bars represent standard deviations.
FIG 7 SIA and GAL binding pocket. A superposition of the stick representa-
tion of the AAV1 SIA binding pocket (in purple) and AAV9 GAL binding site
(in brown) is shown. The predicted glycan binding determinant, residue 470,
is glycine in AAV1 and asparagine in AAV9. This figure was generated using
the PyMOL program (52).
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in cell binding and transduction. The observed increase in cell
binding by the S472R mutation for both viruses did not translate
to an increase in transduction. A three-dimensional (3D) model
of the S472R variant indicates that substitution of the polar serine
residue with the positively charged and larger arginine side chain
conferred the possibility of forming five hydrogen bonds between
the amino group of the arginine and the backbone carbonyl oxy-
gen atoms of residues S268, D270, and N271 and the SIA mole-
cule. These extra interactions may stabilize the capsid to increase
SIA binding affinity. The same stabilizing interactions may pre-
vent post-cell-entry processing events during infection resulting
in the lack of correlation between increased cell binding and trans-
duction.
Given that the residue composition of the SIA binding pocket
is identical between AAV1 and AAV6, the difference in transduc-
tion levels for the T502S mutation in the background of the two
viruses was unexpected (Fig. 4). This observation suggested that
the residues which differ between AAV1 and AAV6 are affecting
this mutant’s phenotype. The variant is defective for cell binding,
suggesting that the surface differences are not playing a role. The
difference in transduction may thus be due to postentry events
associated with the differences at positions 129, 418, and 642. Res-
idues 129, 418, and 642 have been reported to play a role in AAV1
and AAV6 transduction (62, 63). Residue 129 is not ordered in the
AAV structures, while T502 is at a distance of 38.9 and 35.4 Å from
418 and 642, respectively, located on the interior surface of the
capsid. However, how these residues are exerting an effect is dif-
ficult to understand. Regardless of the types of glycan utilized by
different AAV serotypes, the 3-fold protrusions and surrounding
regions have been identified as common glycan binding sites (Fig.
8) (34). At the top of 3-fold protrusion, AAV4 binds to SIA via
K492, K503, M523, G581, Q583, and N585 (64). Structural align-
ment showed that AAV4 K492 and K503, which superpose with
AAV1 S499 and T504, are adjacent to the SIA binding residue
N500 and W503 on AAV1. AAV5 binds to SIA by M569, A570,
T571, A581, G583, T584, Y585, N586, and L587 (65). However,
none of these AAV5 residues is close to the SIA binding site on
AAV1. Rather the residues are located in the depression at the
3-fold axis. AAV6 interacts with HS using K459 and K493, which
are located on the wall of the 3-fold protrusions facing the 5-fold
axis (66). AAV6 also uses K531 and R576, at the base of 3-fold
protrusion facing the 3-fold axis, to interact with HS (26, 66).
K531 is structurally equivalent to K528 on AAV13 and dictates its
HS binding. The residues utilized by AAV2, R484, R487, K532,
R585, and R588, and AAV3B, R594, to interact with HS are also
located at the inner wall of the 3-fold protrusions facing the 3-fold
axis (67–69, 77, 78). These observations, along with the data from
this study, suggest that AAVs have evolved glycan recognition
FIG 8 AAV glycan receptor binding footprints. (A) Available glycan binding sites for AAV1, AAV2, AAV3B, AAV4, AAV5, AAV6, AAV9, and AAV13 projected
onto the surface density of the AAV1 capsid. (B) Closeup of the receptor binding footprints viewed looking down the icosahedral 3-fold axis. Residues involved
in glycan interactions for the different AAV serotypes are listed in the color key. Residues in parentheses indicate AAV1 numbering. The figures were generated
using the PyMOL program (52).
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niches, within the 3-fold region, instead of using the same resi-
dues, to engage their respective glycans during infection.
The prevalence of preexisting antibodies against AAV vectors
limits their therapeutic efficacy (70, 71). To overcome this chal-
lenge, capsid modification based on capsid antigenic epitopes can
generate variants with the ability to escape from antibody recog-
nition (25, 72). The antigenic structures of AAV1, AAV2, AAV5,
AAV6, and AAV8 have been characterized by cryo-electron mi-
croscopy and image reconstruction (41, 58, 73, 74). Despite se-
quence diversity (60 to 99%) between these serotypes, two com-
mon antigenic regions were identified which are located on the
2/5-fold wall and 3-fold protrusion on the capsid surface (41).
Although their mechanisms of neutralization are mostly un-
known, some of these antigenic footprints coincided with regions
determining receptor binding and regions controlling transduc-
tion phenotype. For example, the HS binding site for AAV2 over-
laps with the epitope described for the C37-B MAb specific for this
serotype which binds to the top of 3-fold protrusions (57, 67, 68,
74). This MAb blocks virus entry. On the other hand, A20 MAb,
also directed against AAV2, binds to the 2/5-fold wall described as
a transduction determinant (33, 73). This MAb inhibits infection
at a postnuclear entry step. For AAV5, mutation of its SIA binding
site has also been shown to create variants able to escape from
antibody recognition (65), again pointing to a neutralization
mechanism involving receptor attachment blockage. In the exam-
ple of AAV8, its ADK8 MAb blocks infection at a post-cell/pre-
nuclear-entry step, suggesting a block in cellular trafficking (58).
In this study, the ADK1a was shown to escape recognition by SIA
site mutants S472R, V473D, and N500E, pointing to a receptor
blockage mechanism for neutralization. Information on receptor
attachment sites, as presented here and their potential overlap
with antigenic regions provides an important 3D guide for engi-
neering AAV capsids that can escape from antibody recognition
while retaining their transduction ability.
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